Premium
In reply to the comment of Dr Asaf Achiron to a paper: Circulating anti‐retinal antibodies in response to anti‐angiogenic therapy in exudative age‐related macular degeneration
Author(s) -
KubickaTrząska Agnieszka,
Wilańska Joanna,
RomanowskaDixon Bożena,
Sanak Marek
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.12724
Subject(s) - choroidal neovascularization , macular degeneration , immunofluorescence , ophthalmology , medicine , bevacizumab , retinal , antibody , immunology , chemotherapy
nificantly negatively correlated with disease duration ( 0.551; p < 0.001). Other tests revealed only a slight correlation. In conclusion, we found significant correlations between visual function tests and RNFL thickness with the severity of AD (measured by disease duration). The correlations between the MMSE score and different visual function tests, however, were slight. Colour vision impairments are strongly correlated with disease duration; at this point, therefore, colour vision impairment could be a good biomarker for diagnosis and follow-up of AD. Gundogan et al. (2007) also found that colour vision assessment is better correlated than RNFL thickness with disease activity in other neurodegenerative diseases, such as multiple sclerosis. We only recruited patients with mild to moderate AD, so more studies including patients with mild cognitive impairment and severe AD and with a larger sample size are necessary. Visual function tests, especially colour vision assessment, seem to be more related with neurodegenerative disease progression than other digital imaging techniques such as OCT. Visual impairments are often among the earliest complaints of patients with AD; accordingly, visual function tests (especially colour vision assessment) could facilitate evaluation of suspected AD.